Table 1.

Demographic, clinical, and pathologic characteristics of patients by serum cholesterol status

Cholesterol < 200 mg/dl (n = 518; 61%)Cholesterol ≥ 200 mg/dl (n = 325; 39%)P
Age, mean ± SD60.4 ± 6.360.6 ± 6.40.664a
Race, n (%)0.106b
 Black222 (43)121 (37)
 Non-black296 (57)204 (63)
Year of surgery, median (Q1–Q3)2005 (2003–2008)2004 (2002–2007)<0.001c
Follow-up, median (Q1–Q3)74.7 (41.3–99.0)73.4 (41.5–108.1)0.501c
PSA, median (Q1–Q3)6.3 (4.8–9.4)7.2 (5.0–10.5)0.071c
Statin use, n (%)<0.001b
 Never308 (59)108 (33)
 Started after RP210 (41)217 (67)
BMI, median (Q1–Q3)27.4 (24.7–30.5)27.5 (24.9–30.6)0.936c
Diabetes, n (%)84 (21)48 (20)0.687c
LDL, mean (SD)101.9 (21.6)141.9 (25.4)<0.0001
HDL, mean (SD)43.8 (13.7)51.2 (20.3)<0.0001
Triglycerides, mean (SD)126.0 (83.2)150.0 (83.9)0.0001
Pathologic Gleason score, n (%)0.276b
 2–6177 (34)125 (39)
 7 (3+4)214 (41)134 (41)
 7 (4+3)–10127 (25)66 (20)
Positive margins, n (%)228 (44)141 (43)0.857c
Extracapsular extension, n (%)87 (17)66 (20)0.198c
Seminal vesicle invasion, n (%)44 (8)30 (9)0.713c
Positive lymph nodes, n (%)12 (2)9 (3)0.919c
  • NOTE: P values calculated by at test, bχ2 test, or cWilcoxon rank-sum test.

    Abbreviations: Q1 = 25th percentile; Q3 = 75th percentile.